{
    "clinical_study": {
        "@rank": "53794", 
        "arm_group": [
            {
                "arm_group_label": "Crossover sequence 1", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "Crossover sequence 2", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "Crossover sequence 3", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "Crossover sequence 4", 
                "arm_group_type": "Experimental"
            }
        ], 
        "brief_summary": {
            "textblock": "This Phase 1, open-label, randomized, 4-period crossover study is designed to de termine the\n      relative bioavailability of GDC-0941 administered as a single dose o f the market image\n      formulation at 3 different hardnesses (hardness 1, 2, and 3) and as a single dose of the\n      Phase 2 formulation to healthy male and female volun teers. Participants will be randomly\n      assigned to 4 possible treatment sequences, each comprising 4 periods (1 per formulation),\n      and GDC-0941 will be administere d based on the assigned sequence. The study is expected to\n      last 8 weeks."
        }, 
        "brief_title": "A Study of the Effect of Formulation and Tablet Hardness on the Bioavailability of Pictilisib in Healthy Volunteers", 
        "completion_date": {
            "#text": "May 2014", 
            "@type": "Actual"
        }, 
        "condition": "Healthy Volunteer", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Male and female participants between 18 and 55 years of age, inclusive,\n\n          -  Body mass index (BMI) between 18.5 to 32 kg/m2, inclusive,\n\n          -  Healthy, as determined by no clinically significant findings from medical history,\n             ECG, and vital signs, and who are able to swallow and tolerate a tethered Heidelberg\n             pH Capsule and have gastric pH measurements taken\n\n        Exclusion Criteria:\n\n          -  Any medical condition or history of such condition that may, in the opinion of the\n             investigator, contraindicate participation in this study"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "55 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "24", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "March 18, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02092831", 
            "org_study_id": "GP29284"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Crossover sequence 1", 
                    "Crossover sequence 2", 
                    "Crossover sequence 3", 
                    "Crossover sequence 4"
                ], 
                "description": "Single dose market image tablet of hardness 1", 
                "intervention_name": "GDC-0941", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Crossover sequence 1", 
                    "Crossover sequence 2", 
                    "Crossover sequence 3", 
                    "Crossover sequence 4"
                ], 
                "description": "Single dose market image tablet of hardness 2", 
                "intervention_name": "GDC-0941", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Crossover sequence 1", 
                    "Crossover sequence 2", 
                    "Crossover sequence 3", 
                    "Crossover sequence 4"
                ], 
                "description": "Single dose market image tablet of hardness 3", 
                "intervention_name": "GDC-0941", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Crossover sequence 1", 
                    "Crossover sequence 2", 
                    "Crossover sequence 3", 
                    "Crossover sequence 4"
                ], 
                "description": "Single dose Phase 2 tablet formulation", 
                "intervention_name": "GDC-0941", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "June 2, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Madison", 
                    "country": "United States", 
                    "state": "Wisconsin", 
                    "zip": "53704"
                }
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "4", 
        "official_title": "A PHASE 1, OPEN-LABEL STUDY TO EVALUATE THE EFFECT OF FORMULATION AND TABLET HARDNESS ON THE RELATIVE BIOAVAILABILITY OF PICTILISIB (GDC-0941) IN HEALTHY SUBJECTS", 
        "overall_official": {
            "affiliation": "Hoffmann-La Roche", 
            "last_name": "Clinical Trials", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "May 2014", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "measure": "Area under the concentration-time curve (AUC) of plasma GDC-0941", 
                "safety_issue": "No", 
                "time_frame": "25 Days"
            }, 
            {
                "measure": "Maximum plasma concentration (Cmax) of GDC-0941", 
                "safety_issue": "No", 
                "time_frame": "25 Days"
            }, 
            {
                "measure": "Relative bioavailability (Frel) according to the model independent approach", 
                "safety_issue": "No", 
                "time_frame": "25 days"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02092831"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Incidence of adverse events", 
                "safety_issue": "No", 
                "time_frame": "25 days"
            }, 
            {
                "measure": "Electrocardiogram (ECG)", 
                "safety_issue": "No", 
                "time_frame": "25 days"
            }
        ], 
        "source": "Genentech", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Genentech", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "April 2014", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "June 2014"
    }
}